1. Catalog
  2. The Lead Episode 20: A Discussion of (RAPID): A Mu ...
The Lead Episode 20: A Discussion of (RAPID): A Multicentre, Randomised Trial
Description
Etripamil is a fast-acting, intranasally administered calcium-channel blocker in development for ondemand therapy outside a health-care setting for paroxysmal supraventricular tachycardia. The authors of this randomized trial evaluated the efficacy and safety of etripamil 70 mg nasal spray using a symptom-prompted, repeat-dose regimen for acute conversion of atrioventricular-nodal-dependent paroxysmal supraventricular tachycardia to sinus rhythm within 30 min.
Learning Objectives
  • To understand the findings of the recently published clinical study entitled, "Self-administered intranasal etripamil using a symptomprompted, repeat-dose regimen for atrioventricular-nodal dependent supraventricular tachycardia (RAPID): a multicentre, randomized trial."
Article Authors and Podcast Contributors
Article Authors
Bruce S Stambler, A John Camm, Marco Alings, Paul Dorian, Hein Heidbuchel, Jaco Houtgraaf, Peter R Kowey, Jose L Merino, Blandine Mondésert, Jonathan P Piccini, Sean D Pokorney, Philip T Sager, Atul Verma, J Marcus Wharton, David B Bharucha, Francis Plat, Silvia Shardonofsky, Michael Chen, James E Ip, on behalf of the RAPID Investigators

Podcast Contributors
William H. Sauer, MD, FHRS, CCDS, of Brigham and Women's Hospital
David Chiang, MD, PhD, of Brigham and Women’s Hospital
Sunil Kapur MD, of Brigham and Women's Hospital
Disclosures

 

All relevant financial relationships have been mitigated.

Host Disclosure(s):
W. Sauer: Honoraria/Speaking/Consulting Fee: Biotronik, Biosense Webster, Inc., Abbott, Boston Scientific; Research (Contracted Grants for PIs Named Investigators Only): Medtronic

Contributor Disclosure(s):
D. Chiang: No relevant financial relationships with ineligible companies to disclose. 
S. Kapur: Honoraria/Speaking/Consulting Fee: Biotronik, Abbott, Medtronic, Inc, Novartis


Staff Disclosure(s) (note: HRS staff are NOT in control of educational content. Disclosures are provided solely for full transparency to the learner):
J. Glenn: No relevant financial relationships with ineligible companies to disclose. 
S. Sailor: No relevant financial relationships with ineligible companies to disclose.
Summary
Availability:
On-Demand
Cost:
FREE
Credit Offered:
No Credit Offered
Recommended